Moderated a national surgical session at the Vit-Buckle Society 2025 on treating simultaneous, bilateral detachments using five cases from the last year he treated in Connecticut.
Provided an invited speaker update for the New England Ophthalmology Society 2025 on Phase 2-3 clinical trials for wet macular degeneration and dry macular degeneration.
Discussed cases of CRUNCH syndrome after anti-VEGF treatment in proliferative diabetic retinopathy, and subsequent surgical management at the Connecticut Society of Eye Physicians 2025 meeting.
Presented an overview of AI in retinal diagnosis at Nantucket Retina 2025.
Taught a nation-wide CME course of novel therapies for geographic atrophy.
Summary of Research Project Findings in 2025: >50% of patients tested for a suspect inherited retinal disorder at Retina Consultants P.C. were found to have a pathogenic gene – including a few cases of serious disorders like oculocutaneous albinism and Krabbe’s Disease – significantly increasing diagnostic yield and physician accuracy. In patients with resistant AMD or DME, Faricimab was found to be superior to high dose Eylea when compared head to head. Endophthalmitis cases referred into the retina practice from injections performed by outside providers were significantly less likely to recover vision compared to those from within the practice, due to referral delays.
Papers
Khodor A, Caranfa J, Nanda T, et al. Functional and anatomical outcomes of faricimab in previously treated wet age-related macular degeneration: systematic review and pooled analysis. Ophthalmology Thereapeutics. 2025 Jul [Online, ahead of print]
Li C, Massa A, Krisch M, Gupta N, Raval N, Nanda T, et al. Utility of screening examination for CMV retinitis among patients with CMV viremia. American Journal of Ophthalmology 2025 May [Online, ahead of print].
Dwomoh E, Patel A, Nanda T (Mentoring Author). Three cases of sterile intraocular inflammation in patients receiving both Faricimab and high-dose Aflibercept in consecutive order. Journal of Vitreoretinal Disease [Accepted, pending print].
Edwards C, Nanda T (Mentoring Author). A rare case of retinal vasculitis in a patient with autoimmune lymphoproliferative syndrome.Ophthalmic Surgery Lasers and Imaging Retina. 2025 Jan;56(1):46-49.
Khodor A, Choi S, Nanda T, et al. Visual and anatomic responses in wet age-related macular degeneration (wAMD) patients with a sub-optimal response to anti-VEGF therapy switched to Faricimab. Journal of Vitreoretinal Disease. 2024 Aug; 8(6):643-650.
Posters
Raymond D, Nanda T (Mentoring Author). Clinical utility and diagnostic relevance of instituting outpatient genetic testing for inherited retinal disease in a high-volume retina practice. European Vitreoretinal Society Nov 2025.
Patel A, Nanda T (Mentoring Author). Real-world incidence and characteristics of sterile intraocular inflammation following intravitreal injection with Faricimab and High Dose Aflibercept. European Vitreoretinal Society Nov 2025.
Phillips C, Nanda T (Mentoring Author). Demographic and statistical characteristics of endophthalmitis at a high-volume community retina practice. New England Ophthalmologic Society (NEOS) May 2025.
Patel A, Nanda T (Mentoring Author). Comparative efficacy of increased anti-VEGF inhibition versus dual anti-VEGF/anti-Ang2 inhibition in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion patients with persistent disease activity. Vit Buckle Society Mar 2025.
Dr. Scott Walter
Sept 2025 – presented “Expert Consensus on the Relative Importance of Clinical Risk Factors for Malignancy of Melanocytic Choroidal Lesions” at Retina Society in Chicago, IL
July 2025 – Retina Atlas Chapter of the Year Award, American Society of Retina Specialists
May 2025 – presented “A case-based approach to using Vabysmo®”. Product theater (on behalf of Genentech) at the 23rd Duke Advanced Vitreous Surgery course, Durham NC
March 2025 – presented “Virtual and AI scribing in retina: Current and future trends in clinical documentation for the retina specialist.” 26th annual ASRS Business of Retina meeting, Atlanta GA
March 2025 – participated as a panelist in “Medical Retina Rapid Fire Panel”. 13th annual Vit-Buckle Society meeting, Austin TX
March 2025 – participated in Biosimilar debate: “Anti-VEGF biosimilars are not preferred over their reference products”. 799th New England Ophthalmological Society (NEOS) meeting, Boston MA
Feb 2025 – presented “Current practice patterns in evaluation and management of small tumors: Results of the COOG survey”; and served on Ocular oncologist panel: GPS-guided management of UMTIMPs; at Collaborative Ocular Oncology Group annual meeting, Dallas TX
Nov 2024 – presented “Lessons learned from my coolest uveitis cases.”; and “Management of patients with GA: A case-based expert discussion”. (Product theater on behalf of Apellis); and moderated Uveitis Case Conference at OSN New York Retina meeting, New York NY
October 2024 – “Advanced therapy for retinal vascular diseases: Enhancing durability and reducing treatment burden.” Grand rounds (presented on behalf of Ophthalmology Times) at the American Academy of Ophthalmology meeting, Chicago IL
Sept 2024 – Inducted into the Retina Society and presented “Photodynamic therapy in ocular oncology.” At the 57th annual meeting of the Retina Society, Lisbon, Portugal
Presentations
Sept 2025 – presented “Expert Consensus on the Relative Importance of Clinical Risk Factors for Malignancy of Melanocytic Choroidal Lesions” at Retina Society in Chicago, IL
July 2025 – Retina Atlas Chapter of the Year Award, American Society of Retina Specialists
May 2025 – presented “A case-based approach to using Vabysmo®”. Product theater (on behalf of Genentech) at the 23rd Duke Advanced Vitreous Surgery course, Durham NC
March 2025 – presented “Virtual and AI scribing in retina: Current and future trends in clinical documentation for the retina specialist.” 26th annual ASRS Business of Retina meeting, Atlanta GA
March 2025 – participated as a panelist in “Medical Retina Rapid Fire Panel”. 13th annual Vit-Buckle Society meeting, Austin TX
March 2025 – participated in Biosimilar debate: “Anti-VEGF biosimilars are not preferred over their reference products”. 799th New England Ophthalmological Society (NEOS) meeting, Boston MA
Feb 2025 – presented “Current practice patterns in evaluation and management of small tumors: Results of the COOG survey”; and served on Ocular oncologist panel: GPS-guided management of UMTIMPs; at Collaborative Ocular Oncology Group annual meeting, Dallas TX
Nov 2024 – presented “Lessons learned from my coolest uveitis cases.”; and “Management of patients with GA: A case-based expert discussion”. (Product theater on behalf of Apellis); and moderated Uveitis Case Conference at OSN New York Retina meeting, New York NY
October 2024 – “Advanced therapy for retinal vascular diseases: Enhancing durability and reducing treatment burden.” Grand rounds (presented on behalf of Ophthalmology Times) at the American Academy of Ophthalmology meeting, Chicago IL
Sept 2024 – Inducted into the Retina Society and presented “Photodynamic therapy in ocular oncology.” At the 57th annual meeting of the Retina Society, Lisbon, Portugal
Publications
Song W, Randawa S, Johnson MW, … Walter SD, … Sarraf D. Multifocal vitelliform paravascular retinopathy (MVPR): A new disorder in the vitelliform spectrum. Am J Ophthalmol. 2025;269:362-72.
Dollar JD, Decatur CL, Weis E, … Walter SD, … Harbour JW. Early genetic evolution of driver mutations in uveal melanoma. [Preprint in medRxiv]. 2025: 06.10.25329358.
Harbour JW, Correa ZM, Shefler AC, … Walter SD, … Zhang S. 15-Gene Expression Profile and PRAME as integrated prognostic test for uveal melanoma: First report of the Collaborative Ocular Oncology Group study no. 2. J. Clin Oncol. 2024;42(28):3319-29.
